10x Genomics (TXG) Operating Leases (2020 - 2026)

10x Genomics has disclosed Operating Leases across 7 years of filings, most recently posting $78.8 million for Q2 2026.

• In Q2 2026, Operating Leases fell 9.16% year-over-year to $78.8 million; the TTM figure through Jun 2026 stood at $78.8 million (down 9.16% YoY), while the FY2025 annual figure was $73.4 million, changed 0.07% from the prior year.
• Operating Leases came in at $78.8 million for Q2 2026 at 10x Genomics, down from $81.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $102.0 million in Q1 2023 to a low of $73.3 million in Q4 2024.
• Average Operating Leases over 5 years is $88.6 million, with a median of $86.9 million recorded in 2025.
• Year-over-year, Operating Leases soared 39.81% in 2022 and retreated 13.13% in 2025.
• Over 5 years, Operating Leases stood at $86.1 million in 2022, then slipped by 2.66% to $83.8 million in 2023, then retreated by 12.55% to $73.3 million in 2024, then grew by 0.07% to $73.4 million in 2025, then grew by 7.39% to $78.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $78.8 million in Q2 2026, $81.4 million in Q1 2026, and $73.4 million in Q4 2025.